PDF(Pubmed)
Abstract：
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy approved for the treatment of hematologic malignancies. This therapy leads to a variety of immunologic deficits that could place patients at risk for invasive fungal disease (IFD). Studies assessing IFD in this setting are limited by inconsistent definitions and heterogeneity in prophylaxis use, although the incidence of IFD after CAR T-cell therapy, particularly for lymphoma and myeloma, appears to be low. This review evaluates the incidence of IFD after CAR T-cell therapy, and discusses optimal approaches to prevention, highlighting areas that require further study as well as future applications of cellular therapy that may impact IFD risk. As the use of CAR T-cell therapy continues to expand for hematologic malignancies, solid tumors, and most recently to include non-oncologic diseases, understanding the risk for IFD in this uniquely immunosuppressed population is imperative to prevent morbidity and mortality.
摘要：
嵌合抗原受体（CAR）T细胞疗法是一种新型的免疫疗法，已被批准用于治疗血液系统恶性肿瘤。这种疗法导致多种免疫缺陷，可能使患者面临侵袭性真菌病（IFD）的风险。在这种情况下评估IFD的研究受到预防使用的不一致定义和异质性的限制，虽然在CAR-T细胞治疗后IFD的发生率，特别是淋巴瘤和骨髓瘤，似乎很低。这篇综述评估了CAR-T细胞治疗后IFD的发生率。并讨论了预防的最佳方法，强调需要进一步研究的领域以及可能影响IFD风险的细胞治疗的未来应用。随着CART细胞疗法在血液系统恶性肿瘤中的应用不断扩大，实体瘤,最近包括非肿瘤疾病，了解这种独特的免疫抑制人群的IFD风险对于预防发病率和死亡率至关重要.
